ビオフェルミン製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証1部 | 医薬品 | 4517/E00960 | BIOFERMIN PHARMACEUTICAL CO.,LTD. |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2021/06/11 | 日証協 | 12,830株 | +2.64% | 2,100株 | +23.53% | 28,265株 | +0.76% | 2,013株 | -75.22% |
2021/06/04 | 日証協 | 12,500株 | 0% | 1,700株 | -74.09% | 28,052株 | +20.64% | 8,123株 | +30.89% |
2021/05/28 | 日証協 | 12,500株 | -6.72% | 6,560株 | -43.61% | 23,252株 | -4.75% | 6,206株 | -19.22% |
2021/05/21 | 日証協 | 13,400株 | -33% | 11,633株 | +33.21% | 24,412株 | -30.28% | 7,683株 | +176.07% |
2021/05/14 | 日証協 | 20,000株 | -2.44% | 8,733株 | 0% | 35,012株 | 0% | 2,783株 | +476.19% |
2021/05/07 | 日証協 | 20,500株 | -3.3% | 8,733株 | -73.4% | 35,013株 | -1.41% | 483株 | -76.81% |
2021/04/30 | 日証協 | 21,200株 | +4.95% | 32,832株 | +28.55% | 35,513株 | +1.72% | 2,083株 | -54.72% |
2021/04/23 | 日証協 | 20,200株 | +23.17% | 25,540株 | +9999.99% | 34,913株 | +1.16% | 4,600株 | +420.95% |
2021/04/16 | 日証協 | 16,400株 | -11.83% | 26株 | -87% | 34,513株 | -2.38% | 883株 | -44.81% |
2021/04/09 | 日証協 | 18,600株 | -61.57% | 200株 | -99.14% | 35,356株 | -47.57% | 1,600株 | -93.95% |
2021/04/02 | 日証協 | 48,400株 | +0.21% | 23,200株 | +152.17% | 67,437株 | +2.87% | 26,427株 | -26.59% |
2021/03/26 | 日証協 | 48,300株 | +13.11% | 9,200株 | +820% | 65,556株 | +83.34% | 36,000株 | +800% |
2021/03/19 | 日証協 | 42,700株 | -3.61% | 1,000株 | -95.55% | 35,756株 | -10.29% | 4,000株 | -42.03% |
2021/03/12 | 日証協 | 44,300株 | +0.68% | 22,468株 | +111.24% | 39,856株 | +2.56% | 6,900株 | +137.52% |
2021/03/05 | 日証協 | 44,000株 | +2.33% | 10,636株 | +62.73% | 38,861株 | +3.75% | 2,905株 | +11.73% |
2021/02/26 | 日証協 | 43,000株 | +0.47% | 6,536株 | -72.46% | 37,456株 | +2.45% | 2,600株 | -77.78% |
2021/02/19 | 日証協 | 42,800株 | +4.9% | 23,736株 | +465.14% | 36,560株 | +12.25% | 11,700株 | +290% |
2021/02/12 | 日証協 | 40,800株 | +3.55% | 4,200株 | -68.43% | 32,569株 | -2.54% | 3,000株 | -59.33% |
2021/02/05 | 日証協 | 39,400株 | +5.07% | 13,304株 | +204.58% | 33,419株 | -0.67% | 7,376株 | +63.91% |
※株式分割は考慮していませんのでご注意ください。